^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Ganglioglioma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activation mutation... BRAF/MEK inhibitors...Dabrafenib/trametinib...Vemurafenib/cobimetinib.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancer Control
    Title:

    Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas

    Published date:
    10/08/2021
    Excerpt:
    We describe four patients with BRAF V600 E mutated gliomas, including a 21-year-old woman with a ganglioglioma WHO grade I, a 19-year-old man with a pleomorphic xanthoastrocytoma WHO grade III, and 21-year-old and 33-year-old women with epithelioid GBM WHO grade IV, who achieved durable progression-free survival with combination BRAF/MEKi.
    DOI:
    https://doi.org/10.1177/10732748211040013
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Neurosurg
    Title:

    Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity

    Excerpt:
    The authors treated 4 BRAF V600E patients, each with a different type of primary brain tumor (pilocytic astrocytoma, papillary craniopharyngioma, ganglioglioma, and pleomorphic xanthoastrocytoma) with the combination of dabrafenib and trametinib….A substantial partial response (by RANO [Response Assessment in Neuro-Oncology] criteria) was observed in the patient with ganglioglioma.
    DOI:
    10.3171/2019.8.JNS19643